PATIENT INFORMATION LEAFLET

GLUCOSAMINA KORHISPANA 1500 mg oral powder for solution EFG

Glucosamine Sulfate

Read this leaflet carefully before you start taking this medicine.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you. Do not give it to others, even if they have the same symptoms, as it may harm them.

- If you think you are having a severe side effect or any side effect not listed in this leaflet, inform your doctor or pharmacist.

Glucosamina Korhispana belongs to the group of medications known as other anti-inflammatory and antirheumatic nonsteroidal compounds.

Glucosamina Korhispana is indicated to relieve symptomsproduced by mild to moderate knee arthritis.

Do not take Glucosamina Korhispana:

• If you are allergic (hypersensitive) to glucosamine or to any of the other components of Glucosamina Korhispana.
• If you are allergic (hypersensitive) to shellfish, as glucosamine is obtained from shellfish.

Be especially careful with Glucosamina Korhispana:

• If you have impaired glucose tolerance. Frequent blood sugar level checks may be necessary when starting treatment with glucosamine.
• If you have any risk factors for heart or artery diseases, as in some cases, increases in cholesterol levels have been observed in patients treated with glucosamine.
• If you have asthma. When starting treatment with glucosamine, be aware that symptoms may worsen.
• If you have any kidney or liver impairment, as no studies have been conducted in these conditions and therefore no dosage recommendations can be made.

You should consult your doctor to rule out the presence of other joint diseases for which another treatment should be considered.

Do not take Glucosamina Korhispana if you are under 18 years old.

Use of other medications:

Inform your doctor or pharmacist if you are using or have recently used other medications, including those obtained without a prescription.

Be cautious if taking Glucosamina Korhispana simultaneously with other medications, especially with warfarin and tetracycline. Consult your doctor for proper advice.

Some types of medications used to prevent blood clotting (e.g., warfarin, dicumarol, phenprocoumon, acenocoumarol, and fluindione). The effect of these medications may be potentiated if used in combination with glucosamine. Therefore, patients treated with these combinations should be closely monitored at the start or end of treatment with glucosamine.

Taking Glucosamina Korhispana with food and beverages:

Dissolve the contents of the Glucosamina Korhispana packet in a glass of water and take it once a day, preferably with meals.

Pregnancy and breastfeeding:

Glucosamina Korhispana should not be used during pregnancy.

Glucosamine is not recommended during breastfeeding.

Consult your doctor or pharmacist before using any medication.

Driving and operating machinery:

No studies have been conducted on how Glucosamina Korhispana affects the ability to drive and operate machinery. However, if you experience dizziness or drowsiness when taking Glucosamina Korhispana, you should not drive or operate machinery (see section 4 "Possible side effects").

Important information about some of the components of Glucosamina Korhispana:

Patients with low-sodium diets should note that this medication contains 151 mg (6.57 mmol) of sodium per packet.

This medication contains sorbitol. If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking/using this medication.

This medication may be harmful to individuals with phenylketonuria because it contains aspartame, which is a source of phenylalanine.

Follow exactly the administration instructions for Glucosamina Korhispana as indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.

Your doctor will adjust the dosage according to your condition.

Administration method and dosage:

The usual starting dose is one packet (dissolved in a glass of water) once a day, preferably with meals.

For oral use.

Treatment duration:

Glucosamine is not indicated for the treatment of acute painful symptoms. Relief of symptoms (especially pain relief) may not be evident until after several weeks of treatment, and in some cases even longer. If you do not experience symptom relief after 2-3 months, the continuation of treatment with glucosamine should be reconsidered.

If you take more Glucosamina Korhispana than you should:

If you take more Glucosamina Korhispana than you should, or if another person or child takes this medication, inform your doctor or pharmacist.

Signs and symptoms of glucosamine overdose include headache, dizziness, confusion, joint pain, nausea, vomiting, diarrhea, or constipation. Do not continue taking Glucosamina Korhispana at the first sign of the mentioned symptoms.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service. Phone: (91) 562-04-20, indicating the medication and the amount taken.

If you forgot to take Glucosamina Korhispana:

Do not take a double dose to compensate for the missed doses.

If you have any other questions about the use of this product, ask your doctor or pharmacist.

Like all medications, Glucosamina Korhispana may produce adverse effects, although not all people will experience them.

You should discontinue treatment with glucosamina and seek immediate medical attention if you experience symptoms of angioedema, such as:

• Swelling of the face, tongue, or throat.
• Difficulty swallowing.
• Urticaria and difficulty breathing.

The most frequently observed are:

Frequent (affects 1 to 10 of every 100 people)

• Headache.
• Fatigue.
• Nausea.
• Abdominal pain.
• Indigestion.
• Diarrhea.
• Constipation.

Rare (affects 1 to 10 of every 1,000 people)

• Rash.
• Itching.
• Redness.
• Vomiting.

Unknown frequency (cannot be estimated from available data)

• Dizziness.
• Worsening of asthma symptoms.
• Swelling in ankles, legs, and feet.
• Urticaria.
• Increased levels of cholesterol and worsening of blood sugar levels in diabetes mellitus.

If you consider any of the adverse effects you are experiencing to be severe or if you notice any adverse effect not mentioned in this prospectus, report it to your doctor or pharmacist.

This medication does not require special conditions for conservation.

Keep out of the reach and sight of children.

Do not use Korhispana Glucosamine after the expiration datethatappears on the package and container after the abbreviation CAD. The expiration date is the last day of the month indicated.

Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medicines that you no longer need.This will help protect the environment.

Composition of Glucosamina Korhispana:

The active principle is glucosamine. Each packet of Glucosamina Korhispana contains 1,500 mg of glucosamine sulfate as sodium chloride glucosamine sulfate, equivalent to 1,178 mg of glucosamine.

The other components are: aspartame (E951), sorbitol (E420), sodium, citric acid, and macrogol 4000

Appearance of the product and contents of the packaging:

Glucosamina Korhispanais presented in single-dose packets containing powder for oral solution. Each package contains 20 or 30 packets.

Holder of the marketing authorization andresponsible for manufacturing:

This prospectus has been reviewed in November 2021